Martina S. Lutz

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancer.

Targeting NKG2DLs with an ADCC enhanced fusion protein for induction of NK cell reactivity against ovarian cancer.

Journal: Journal of ovarian research

Published: September 04, 2025

Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).

Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).

Journal: ImmunoTargets and therapy

Published: April 17, 2025

Preclinical Evaluation of a B7-H3 Targeting Antibody Enhancing NK Cell-Mediated Cytotoxicity for Ovarian Cancer Treatment.

Preclinical Evaluation of a B7-H3 Targeting Antibody Enhancing NK Cell-Mediated Cytotoxicity for Ovarian Cancer Treatment.

Journal: ImmunoTargets and therapy

Published: March 06, 2025

Effects of a mindfulness intervention on emotion differentiation and heart rate variability.

Effects of a mindfulness intervention on emotion differentiation and heart rate variability.

Journal: Frontiers in human neuroscience

Published: October 22, 2024

Targeting CD276 for T cell-based immunotherapy of breast cancer.

Targeting CD276 for T cell-based immunotherapy of breast cancer.

Journal: Journal of translational medicine

Published: June 14, 2024

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.

Journal: Blood cancer journal

Published: February 26, 2024

An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.

An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.

Journal: Frontiers in immunology

Published: November 24, 2023

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Journal: Nature communications

Published: June 14, 2023

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.

Journal: Frontiers in immunology

Published: February 10, 2023

An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.

An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: October 06, 2022

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression.

Journal: Frontiers in oncology

Published: April 11, 2022

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc).

Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc).

Journal: Oncoimmunology

Published: January 27, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026